Skip to content
Canada /Our focus /Neuroscience

Neuroscience

Johnson & Johnson Innovative Medicine’s history is closely tied to neuroscience. The very first medication developed by Dr Paul Janssen, our company founder, was for the treatment of schizophrenia. It set us on a path of discovery and development.
Female wheelchair athlete having sport activity outdoors with her boyfriend
Science is only part of the story
You’re not alone: one in five of us will be affected by a mental health disorder in our lifetime1. For those affected and their loved ones, the impact of mental illness is often vast. We are determined to continue increasing our understanding of mental illness to reduce the disability and devastation caused by serious neuropsychiatric and neurodegenerative diseases.
Expand
Our mission is to develop new solutions to improve and transform the lives of people living with mental illness. We are committed to improving the way in which mental health disorders are diagnosed and treated to change the lives of people living with mental illness.
Collapse
Approximately 8% of Canadian adults will experience major depression at some time in their lives. It’s the leading cause of disability worldwide with high unmet need.
Approximately 1% of Canadians are affected by schizophrenia, a treatable yet complex mental illness that affects how a person thinks, feels, behaves and relates to others. It is believed to be caused by a combination of biological and environmental factors that contribute to its development.2

1 Mental Health Commission: Strengthening the Case for Investing Backgrounder. Link accessed May 17th, 2021
2 Centre for Addiction and Mental Health (CAMH): Schizophrenia link
3 CAMH: Psychosis link